Human Anti-GIPR Recombinant Antibody (clone Gipg013) (CAT#: PABL-103)

Recombinant Human Antibody (Gipg013) is capable of binding to GIPR, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-GIPR mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-GIPR mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody is a specific competitive antagonist with equally high potencies to mouse, rat, dog, and human GIP receptors with a Ki of 7 nm for the human GIPr. Gipg013 antagonizes the GIP receptor and inhibits GIP-induced insulin secretion in vitro and in vivo.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Antagonism of GIP induced cAMP production in GIPr over-expressing cell lines.

Figure 1 Antagonism of GIP induced cAMP production in GIPr over-expressing cell lines.

Gipg013 and Gipg133 were characterised for GIPr antagonism in cell based cAMP HTRF® assay and data plotted using nonlinear regression. Panel A and B show antagonistic profiles from HEK293s cells overexpressing human, mouse, rat, and, dog GIPr using Gipg013 and Gipg133 IgGs, respectively,. Panel C and D show antagonistic and agonistic profiles in the human GIPr assay for GIP7-30 and Pro3GIP and GIP. Values have been normalised to the maximum activity of GIPr, which is defined by total cellular cAMP produced in the agonism assay on in the absence of peptide/IgG in the antagonism assay. ●, human; ■, mouse; ▼, rat; ▲, dog; ♦, isotype control IgG1; *, GIP; +, GIP7-30; ×, Pro3GIP.

Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'brien, S.,... & Benthem, L. (2013). Structural and pharmacological characterisation of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. Journal of Biological Chemistry, jbc-M112.

Figure 2 Antibody cell binding and inhibition of ligand binding.

Figure 2 Antibody cell binding and inhibition of ligand binding.

A, Binding of Gipg013 to GIPr and related receptors on overexpressing cells. Direct binding of 0.25 µg/ml Gipg013 IgG to h, human; d, dog; m, mouse; or r, rat orthologs of the glucagon (GCGr), GLP-1 (GLP-1r) or GIP (GIPr) receptors. Control for non-specific binding on GIPr orthologs, NIP228_TM, at 0.25 µg/ml. Data shown is representative of two separate experiments for the human receptors and a single experiment for the rodent and canine receptors. B, receptor ligand competition assay showing IC50 determination of Gipg013 IgG binding to GIPr overexpressing cells. □, Gipg013; ▲, isotype control IgG1.

Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'brien, S.,... & Benthem, L. (2013). Structural and pharmacological characterisation of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. Journal of Biological Chemistry, jbc-M112.

Figure 3 Analysis of Gipg013 antagonism of GIPr.

Figure 3 Analysis of Gipg013 antagonism of GIPr.

A, GIP dose response curves in the presence of Gipr013. Non linear regression plot of dose effect curve for GIP was determined in the presence of various concentrations of Gipg013 IgG. ∇, 3750 nM; ∆, 1250 nM; □, 417 nM; ○, 139 nM; ♦, 46 nM; ▼15 nM; ▲, 5 nM; ■, 1.7 nM; ●, 0 Gipg013. B, Schild plot analysis of dose response curves. The Schild plot intersects the abscissa at pA2 (=KD).

Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'brien, S.,... & Benthem, L. (2013). Structural and pharmacological characterisation of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. Journal of Biological Chemistry, jbc-M112.

Figure 4 Inhibition of GIP induced insulin secretion.

Figure 4 Inhibition of GIP induced insulin secretion.

Panels A and B show inhibition of GIP stimulation in a glucose stimulated insulin secretion assay with dispersed rat islets. A, The the effect of GIP on top of the glucose stimulated insulin secretion (open bars) and the inhibition of this effect with 600 nM Gipg013 (filled bars). B, The GIP enhanced insulin secretion was inhibited with Gipg013 at concentrations of both 300 nM and 600 nM. Panel C shows Inhibition of GIP induced insulin secretion in vivo. Insulin response measured as the relative insulin AUC0-30 min between period one and two for GIP induced insulin secretion in anesthetized rats, AUC1 before and AUC2 30 minutes after Gipg013 infusion. Insulin response = AUC2/AUC1*100. n=6 for vehicle and n=3 for Gipg013. *p<0.05 between vehicle and Gipg013.

Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'brien, S.,... & Benthem, L. (2013). Structural and pharmacological characterisation of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. Journal of Biological Chemistry, jbc-M112.


Specifications

  • Immunogen
  • Human gastric inhibitory polypeptide receptor
  • Host Species
  • Human
  • Type
  • Human IgG
  • Specificity
  • Human GIPR
  • Species Reactivity
  • Human
  • Clone
  • Gipg013
  • Applications
  • ELISA, Block, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody was validated for Antagonism and Inhibition. For details, refer to published data.

Target

  • Alternative Names
  • GIPR; gastric inhibitory polypeptide receptor; PGQTL2; GIP-R; glucose-dependent insulinotropic polypeptide receptor

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone Gipg013"

See other products for "GIPr"

Single-domain Antibody

CAT Product Name Application Type
NAB-1106-sdAb Recombinant Anti-Human GIPr VHH Single Domain Antibody IP, ChiP, IHC, ELISA Llama VHH

Blocking Antibody

CAT Product Name Application Type
NEUT-880CQ Mouse Anti-GIPR Recombinant Antibody (clone CBL380) Block, FC, IHC, CyTOF® Mouse IgG1

Neutralizing Antibody

CAT Product Name Application Type
NEUT-881CQ Mouse Anti-GIPR Recombinant Antibody (clone CBL804) Neut, FC, CyTOF® Mouse IgG2a
NEUT-882CQ Mouse Anti-GIPR Recombinant Antibody (clone CBL805) Neut, FC, CyTOF® Mouse IgG1

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-1443 Hi-Affi™ Rabbit Anti-GIPR Recombinant Antibody (clone DS1443AB) WB, IHC, ICC, FC Rabbit IgG

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-103. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare